Moleculin Biotech Inc MBRX 深 滬
等待開盤 10-04 09:30:00 美东时间
0.4617
-0.038
-7.66%
華盛通- 最 高0.499
- 今 開0.49
- 成交量 406.81万股
- 最 低 0.415
- 昨 收 0.50
- 總市值 1696.26万
- 52周最高 3.6499
- 市盈率 靜 --
- 換手率 11.07%
- 52周最低 0.25
- 委 比 -90.79%
- 總股本 3673.94万
- 歷史最高 862.20
- 量 比 1.00
- 振 幅 16.80%
- 歷史最低 0.25
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Moleculin Biotech Secures Canadian Patent Titled "PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE"
Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance f
09-25 20:40
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
<p>Moleculin Biotech 宣布，加拿大知识产权局已批准其关于生产高稳定性和高纯度的前脂质体Annamycin冻干粉的方法的专利申请。该专利预计将于未来几个月内正式授权，基本专利期限将持续至2040年。Annamycin 是一种新型药物候选，旨在成为首个获批的非心脏毒性蒽环类药物，目前正针对急性髓性白血病（AML）和软组织肉瘤肺转移（STS肺转移）进行开发。此外，该药物还显示出在治疗多种癌症类型方面的潜力。Moleculin公司正在加强其在全球范围内的知识产权组合，此前已在美欧获得相关专利授权。公司首席执行官Walter Klemp表示，将继续致力于通过强化知识产权保护，推动Annamycin成为治疗难治性肿瘤的变革性候选药物。</p>
09-25 12:35
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
Moleculin Biotech announced expansion of its Phase 2B/3 MIRACLE trial for AnnAnnAraC in AML treatment, adding sites in the US, Spain, Georgia, Poland, Romania, Italy, and Lithuania. The company expects to recruit 20 subjects by September and reach 45 by Q4 2025 for initial data unblinding, aiming for Part A completion in early 2026 and Part B launch thereafter. The trial's adaptive design allows early evaluation of efficacy and safety, with optim...
09-09 12:45
Moleculin Biotech Begins Phase 2B/3 MIRACLE Trial Enrollment
Moleculin Biotech ( ($MBRX) ) just unveiled an announcement. On September 8, 20...
09-08 21:03
Moleculin Announces It Has Dosed The First EU Patient In It's Phase 3 MIRACLE Trial For Treatment Of Acute Myeloid Leukemia
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced
09-08 20:31
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
Moleculin Biotech has enrolled the first two subjects, with one treated, in its Phase 2B/3 MIRACLE trial for relapsed/refractory acute myeloid leukemia (R/R AML) in Spain. The trial aims to recruit 45 subjects by end-2025 for initial data unblinding. Sites are active in the US, Spain, Ukraine, Georgia, and Romania, with more expected by September. The MIRACLE trial, studying Annamycin in combination with cytarabine, targets 45 subjects for early ...
09-08 12:30
Reported Earlier: Moleculin Biotech Raises $6M From Immediate Exercise Of 16.2M Warrants At $0.37/Share; Issues 64.9M New Warrants At $0.55/Share
Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has
08-29 00:51
Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds
Moleculin Biotech, Inc. entered into agreements to exercise warrants for up to 16.2 million shares at $0.37 per share, generating approximately $6 million in gross proceeds. In exchange, the company issued new warrants for up to 64.9 million shares at $0.55 per share, exercisable upon shareholder approval. The transaction is expected to close on August 28, 2025, with proceeds used for working capital and general corporate purposes. Roth Capital P...
08-28 12:30
Moleculin Biotech Completes Phase 1B/2 Clinical Trial Evaluating Annamycin In Combination With Cytarabine For Acute Myeloid Leukemia
Median Overall Survival (OS) of 15 months for subjects with complete remission (n=8)Median OS of 2nd Line efficacy evaluable population of 12 months (n=9)Median OS of Intent to Treat population (1L-7L) of 9 months
08-27 20:48
